A mechanism-based pharmacokinetic-enzyme model for cyclophosphamide autoinduction in breast cancer patients

British Journal of Clinical Pharmacology

Volumn 48, Issue 5, 1999, Pages 669-677

  Hassan, Moustapha ^a   Svensson, U S H ^b   Ljungman, P ^a   Bjorkstrand B ^a   Olsson, H ^b   Bielenstein, M ^c   Abdel Rehim, M ^d   Nilsson, C ^a   Johansson, M ^c   Karlsson, M O ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c Apoteksbolaget Central Laboratory   (Sweden)

^d UPPSALA UNIVERSITY   (Sweden)

Author keywords

4 Hydroxycyclophosphamide; Autoinduction; Breast cancer; Cyclophosphamide; Enzyme induction model; Pharmacokinetics

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; AZIRIDINE DERIVATIVE; CARBOPLATIN; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; THIOTEPA;

ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; COMPARTMENT MODEL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; ENZYME INDUCTION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; BIOTRANSFORMATION; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; FEMALE; HALF-LIFE; HUMANS; MIDDLE AGED; MODELS, BIOLOGICAL;

EID: 0032708007     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1999.00090.x     Document Type: Article

References (53)

1. 1 Moore MJ. Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet 1991; 20: 194-208.
2. 2 Ren S, Yang J-S, Kalhorn TF, Slattery JT. Oxidation of cyclophosphamide to 4-hydroxycyclophosphamide and deschloroethylcyclophosphamide in human liver microsomes. Cancer Res 1997; 57: 4229-4235.
3. 3 Low JE, Borch RF, Sladek NE. Conversion of 4-hydroxycyclophosphamide to phosphoramide mustard and acrolein mediated by bifunctional catalysts. Cancer Res 1982; 42: 830-837.
4. 4 Colvin M, Brundrett RB, Kan MN, Jardine I, Fenselau C. Alkylating properties of phosphoramide mustard. Cancer Res 1976; 36: 1121-1128.
5. 5 Chang TKH, Weber GF, Crespi CL, Waxman DJ. Differential activation of cyclophosphamide and ifosphamide by cytochrome P-450 2B and 3A in human liver microsomes. Cancer Res 1993; 53: 5629-5637.
6. 6 Chang TKH, Yu L, Goldstein JA, Waxman DJ. Identification of polymorphically expressed CYP2C19 and the wild type CYP2C9-Ile359 allele as low Km catalysts of cyclophosphamide and ifosfamide activation. Pharmacogenetics 1997; 7: 211-221.
7. 7 Connors TA, Cox PJ, Farmer PB, Foster AB, Jarman M. Some studies of the active intermediates formed in the microsomal metabolism of cyclophosphamide and isophosphamide. Biochem Pharmacol 1974; 23: 115-129.
8. 8 Fenselau C, Kan MNN, Rao SS, et al. Identification of aldophosphamide as a metabolite of cyclophosphamide in vitro and in vivo in humans. Cancer Res 1977; 37: 2538-2543.
9. 9 Domeyer BE, Sladek NE. Metabolism of 4-hydroxycyclophosphamide/aldophosphamide in vitro. Biochem Pharmacol 1980; 29: 2903-2912.
10. 10 Lindahl R. Aldehyde dehydrogenases and their role in carcinogenesis. Crit Rev Biochem Mol Biol 1992; 27: 283-335.
11. 11 Ruzicka JA, Ruenitz PC. Cytochrome P-450 mediated N-dechloroethylation of cyclophosphamide and ifosfamide in the rat. Drug Metab Dispos 1992; 20: 770-772.
12. 12 Bohnenstengel F, Hofmann U, Eichelbaum M, Kroemer HK. Characterization of the cytochrome P450 involved in side-chain oxidation of cyclophosphamide in humans. Eur J Clin Pharmacol 1996; 51: 297-301.
13. 13 Graham MI, Shaw IC, Souhami RL, et al. Decreased plasma half-life of cyclophosphamide during repeated high-dose administration. Cancer Chemother Pharmacol 1983; 10: 192-193.
14. 14 Moore MJ, Hardy RW, Thiessen JJ, Soldin SJ, Erlichman C. Rapid development of enhanced clearance after high-dose cyclophosphamide. Clin Pharmacol Ther 1988; 44: 622-628.
15. 15 Fasola G, Lo Greco P, Calori E, et al. Pharmacokinetics of high-dose cyclophospahmide for bone marrow transplantation. Haematologica 1991; 76: 120-125.
16. 16 Sladek NE, Priest J, Doeden D, et al. Plasma half-life and urinary excretion of cyclophosphamide in children. Cancer Treat Rep 1980; 64: 1061-1066.
17. 17 Chang TKH, Yu L, Maurel P, Waxman DJ. Enhanced cyclophosphamide and ifosfamide activation by primary human hepatocyte culture: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Cancer Res 1997; 57: 1946-1953.
18. 18 Chen T, Passos-Coelho J, Noe D, et al. Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation. Cancer Res 1995; 15: 810-816.
19. 19 Boddy AV, Cole M, Pearson ADJ, Idle JR. The kinetics of the auto-induction of ifosfamide metabolism during continous infusion. Cancer Chemother Pharmacol 1995; 36: 53-60.
20. 20 Hardy RW, Erlichman C, Soldin SJ. High-performance liquid chromatographic measurement of cyclophosphamide in serum. Ther Drug Monit 1984; 2: 313-318.
21. 21 Johansson M, Biclenstein M. Determination of 4-hydroxycyclophosphamide in plasma, as 2,4-dinitrophenylhydrazone derivative of aldophosphamide, by liquid chromatography. J Chromatogr 1994; 660: 111-120.
22. 22 Beal SL, Sheiner LB. NONMEM Users'Guides, NONMEM. Project Group, University of California at San Francisco, San Francisco, 1998.
23. 23 Jonsson EN, Karlsson MO. Xpose - an S-PLUS based population pharmacokinetic-pharmacodynamic model building aid for NONMEM. Comp Meth Prog Biomed 1998; 58: 51-64.
24. 24 Schuler U, Ehninger G, Wagner T. Repeated high-dose cyclophosphamide administration in bone marrow transplantation: exposure to activated metabolites. Cancer Chemother Pharmacol 1987; 20: 248-252.
25. 25 Yule SM, Boddy AV, Cole M, et al. Cyclophosphamide pharmacokinetics in children. Br J Clin Pharmacol 1996; 41: 13-19.
26. 26 Scheyer RD, Cramer JA, Mattson RH. A pharmacodynamic approach to the estimate of carbamazepine autoinduction. J Pharm Sci 1994; 83: 491-494.
27. 27 Waxman DJ, Azaroff L. Phenobarbital induction of cytochrome P-450 gene expression. Biochem J 1992; 281: 577-592.
28. 28 Whitlock JPJ, Denison MS. Induction of cytochrome P450 enzymes that metabolize xenobiotics. In Cytochrome P450; structure mechanism, biochemistry 2nd edn. Ortiz de Montellano P, New York and London: Plenum Press, 1995; 374-378.
29. 29 von Bahr C, Steiner E, Koike Y, Gabrielsson J. Time course of enzyme induction in humans: effect of pentobarbital on nortriptyline metabolism. Clin Pharmacol Ther 1998; 64: 18-25.
30. 30 Abramson FP. Kinetic models of induction: I. Persistence of the inducing substance. J Pharm Sci 1986; 74: 223-228.
31. 31 Abramson F, Lutz M. The kinetics of induction by rifampin of alpha 1-acid glycoprotein and antipyrine clearance in the dog. Drug Metab Dispos 1986; 14: 46-51.
32. 32 Watkins PB, Wrighton SA, Maurel P, et al. Identification of an inducible form of cytochrome P-450 in human liver. Proc Natl Acad Sci U S A 1985; 82: 6310-6314.
33. 33 Jao JY, Jusko WJ, Cohen JL. Phenobarbital effects on cyclophosphamide pharmacokinetics in man. Cancer Res 1972; 32: 2761-2764.
34. 34 Gentile DM, Tomlinson ES, Maggs JL, Park BK, Back DJ. Dexamethasone metabolism by human liver in vitro. Metabolite identification and inhibition of 6-hydroxylation. J Pharmacol Exp Ther 1996; 277: 105-112.
35. 35 Ren S, Kalhorn TF, McDonald GB, et al. Pharmacokinetics of cyclophosphamide and its metabolites in bone marrow transplantation patients. Clin Pharmacol Ther 1998; 64: 289-301.
36. 36 Chang TK, Yu L, Maurel P, Waxman DJ. Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction of oxazaphosphorines. Cancer Res 1997; 57: 1946-1954.
37. 37 Warren JW, Benmaman JD, Wannamaker BB, Levy RH. Kinetics of carbamazepine-ethosuximide interaction. Clin Pharmacol Ther 1980; 28: 646-651.
38. 38 Rostami-Hodjegan A, Wolff K, Hay A, et al. Population pharmacokinetics of methadone in opiate users: characterization of time-dependent changes. Br J Clin Pharmacol 1999; 48: 43-52.
39. 39 Jerling M, Lindström L, Bondesson U, Bertilsson L. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: Evidence from a therapeutic drug monitoring service. Ther Drug Monit 1994; 16: 368-374.
40. 40 Hardwick JP, Gonzalez FJ, Kasper CB. Cloning of DNA complementary to cytochrome P-450 induced by pregnenolone-16 apha-carbonitrile. Characterization of its mRNA, gene, and induction response. J Biol Chem 1983; 258: 10182-10186.
41. 41 Ravishankar H, Padmanaban G. Turnover of messenger RNA, apoprotein and haem of cytochrome P 450b+e induced by phenobarbitone in rat liver. Biochem J 1985; 229: 73-79.
42. 42 Houston JB. Drug metabolite kinetics. Pharmacol Ther 1982; 15: 521-552.
43. 43 Kunze KL, Wienkers LC, Thummel KE, Trager WF. Warfarin-fluconazole. I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies. Drug Metab Dispos 1996; 24: 414-421.
44. 44 Black DJ, Kunze KL, Wienkers LC, et al. Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies. Drug Metab Dispos 1996; 24: 422-428.
45. 45 Kazierad DJ, Martin DE, Blum RA, et al. Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers. Clin Pharmacol Ther 1997; 62: 417-425.
46. 46 Kaukonen KM, Olkkola KT, Neuvonen PJ. Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174. Eur J Clin Pharmacol 1998; 53: 445-449.
47. 47 Anderson L, Chen T, Colvin O, et al. Cyclophosphamide ad 4-hydroxycyclophosphamide/aldophosphamide kinetics in patients receiving high-dose cyclophosphamide. Clin Cancer Res 1996; 2: 1481-1487.
48. 48 Romkes M, Faletto MB, Blaisdell JA, Raucy JL, Goldstein JA. Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. Biochemistry 1991; 30: 3247-3255.
49. 49 Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270: 414-423.
50. 50 Brock N, Gross R, Hohorst H-J, Klein HO, Schneider B. Activation of cyclophosphamide in man and animals. Cancer 1971; 27: 1512-1529.
51. 51 Wilkinson PM, O'Neill PA, Thatcher N, Lucas SB. Pharmacokinetics of high-dose cyclophosphamide in patients with metastatic bronchogenic carcinoma. Can Chem Pharmacol 1983; 11: 196-199.
52. 52 Chan KK, Hong PS, Tutsch K, Trump DL. Clinical pharmacokinetics of cyclophosphamide and metabolites with and without SR-2508. Cancer Res 1994; 54: 6421-6429.
53. 53 Chen T-L, Kennedy MJ, Anderson LW, et al. Nonlinear pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide/aldophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation. Drug Met Dispos 1997; 25: 544-551.